Back to top

Support translational science and transform discoveries into cures

By funding research projects on Molecule, you actively contribute to a better future for humanity. Your funds support scientific breakthroughs that have the potential to improve healthcare, address environmental challenges, and drive innovation in various industries.

Benefits

For Funders

This is what Molecule and the ecosystem has to offer you.

01

Impactful Contributions

Impactful Contributions

Impactful Contributions

As a funder at Molecule, you have the opportunity to make meaningful contributions to scientific research and development. By supporting research projects within the Molecule ecosystem, you directly contribute to advancements in fields such as longevity, synthetic biology, women's health, psychedelics, cryogenics and hair loss. Your funding has the potential to drive positive change and improve the lives of individuals and communities.

02

Access to Cutting-Edge Research

Access to Cutting-Edge Research

Access to Cutting-Edge Research

By funding projects on Molecule, you gain access to cutting-edge research and scientific discoveries. You will be at the forefront of knowledge and innovation, staying informed about the latest breakthroughs in various fields of study. This access can provide you with unique insights, networking opportunities, and potential collaborations with renowned researchers and scientists.

03

Transparent and Accountable Ecosystem

Transparent and Accountable Ecosystem

Transparent and Accountable Ecosystem

Transparency and accountability are core principles at Molecule. As a funder, you can expect a transparent ecosystem where information about research projects, funding utilization, and outcomes is readily available. This transparency fosters trust and allows you to track the progress of projects you have supported, ensuring that your investments are being utilized effectively and ethically.

04

Engaging in a Collaborative Community

Engaging in a Collaborative Community

Engaging in a Collaborative Community

As a funder at Molecule, you become part of a collaborative community of like-minded individuals who share a passion for advancing scientific discovery. You can engage in discussions, share ideas, and collaborate with researchers, scientists, and fellow funders. This community provides a unique platform for networking, knowledge-sharing, and fostering meaningful connections in the world of science.

$30M+

Funds in the Ecosystem

17+

Research projects funded

15.7K+

Community Members

For funders

Fund Science

By funding you are empowering researchers and scientists, you play a crucial role in shaping a future where scientific discoveries benefit all and where people have control over their own health and well-being.

Ecosystem Overview

Decentralised global communities of science or BioDAOs that are part of Bio.xyz

Funding Entity
Category
Treasury
Total Projects
Funded
Token
Forum
Longevity
$ 8,825,000
21
-
$ 4,210,000
Women's Health
$ 432,000
2
-
$220,000
Hair Loss
$ 3,320,000
1
-
$ 119,000
Synthetic Biology
$ 836,000
1
-
£ 249,000
Psychedelics
$ 100,000
3
-
$ 6,000
Cryopreservation
$ 200,000
-
$ 35,000
For Funders

IP-NFTs

Discover and contribute to advancements in fields such as longevity, reproductive health, hair-loss, cryopreservation or psychedelics. Find cutting edge projects and new opportunities.

Collaborate

Engage in Collaboration

Actively participate in the DeSci / Molecule community by collaborating with researchers, and fellow funders. Share your expertise, insights, and network to contribute to the collective intelligence that drives innovation.

Science Successfully Funded

Our most recent and exciting research projects that have successfully secured funding.

Learn

Learn more about Molecule

Stay informed and inspired. Explore Molecule’s news and fresh content.

Cameron Stow
Jun 13, 2024
min read

Day 1

Molecule Announced Catalyst

Of course, we can’t talk about DeSci.Berlin without highlighting the unveiling of our latest product—Catalyst. In case you missed our announcement, Catalyst is a platform designed to revolutionize the funding and governance of early-stage research. It operates like the Kickstarter of science, enabling funders to contribute crypto directly to research projects and govern the resulting IP, fostering meaningful connections between researchers and funders.

As we prepare for Catalyst’s beta launch, we invite you to join us on this journey and be among the first to experience the future of research funding and project governance. Secure your spot on the early access list today!

Julia Zhao from Nucleate - “Empowering Biotech Leaders: From Academic Science to Accelerated Startups”

Nucleate’s Global Director of Activator Operations, Julia Zhao, presented how biotech leaders can better transition from academic science to founding and scaling startups. She highlighted Nucleate’s flagship program, Activator, which facilitates company formation in the life sciences through a structured matching process and curriculum. Through this program, Nucleate provides mentorship, expert workshops, and industry connections to help teams develop their projects.

What stuck out for us was Julia’s focus on the importance of community and open access to biotech education. She says, “Nucleate is currently aiming to be the world's largest educational organization for functional and impact-driven life science career development programs.”

For more information about the Nucleate x Molecule partnership, you can read the full press release here.

Vincent Weisser - “Scientific Progress Through Decentralized AI”

Vincent Weisser recently honed his focus on democratizing AI at scale by founding Prime Intellect. Their platform simplifies finding global compute resources and training state-of-the-art models through distributed training across clusters. AI will increasingly drive and accelerate scientific progress, and Vincent understands the necessity of decentralization. 

With the growing capabilities of large language models (LLMs) and AI agents, we can expect remarkable advancements in technology and science, and better access to scaled compute is crucial as this happens. 

Vincent reiterated DeSci's role in this: design ecosystems that provide necessary rewards/incentives and build bioDAOs that can allocate capital for compute resources.

Jurij Skornik & Charlie Edwards - DeSci on Decentralized Knowledge Graphs with Origin Trail

The last three major knowledge revolutions were the printing press, the internet, and now AI. According to Jurij, the future of AI will be unlocked through what he calls the “Verifiable Internet for AI,” a combination of crypto, the internet, and AI that ensures the provenance, ownership, and integrity of information. By integrating Decentralized Knowledge Graphs (DKGs) and “Knowledge Assets” using the Origin Trail framework, we can obtain much more reliable outputs from AI. These Knowledge Assets can be grouped into knowledge bundles called “Paranets,” which can then be mined and monetized, incentivizing participation from knowledge miners.

Charlie, from ID Theory, shared with us their plan to invest in building a DeSci Paranet to create a “ground truth layer for autonomous research and decentralized scientific advancement.” - if you’re a builder in this space, be sure to drop them a message!

To learn more about Origin Trail, visit their website or check out their latest tool, ChatDKG.

Ethan Perlstein - “Scientific Progress Through Decentralized AI”

Ethan Perlstein is a vision-driven man, determined to help families abandoned by traditional healthcare. He spoke to us about his company Perlara, the world's first biotech public benefit corporation. Perlara collaborates directly with motivated families to develop treatments and cures for rare genetic diseases, operating as a decentralized, patient-driven biotech company. Ethan thinks that Web3 technologies have the potential to scale the patient-driven biotech model, ensuring economic fairness and proper compensation for families’ contributions. We agree!

"Pharma is too big to scale down to this problem... I'd love a world where families are not just expected to sit down and wait for medicine to show up. They should be rewarded for their contributions to drug development, potentially through a value-added royalty system on-chain."

Day 2

Lou de Kerhuelvez - Opportunities for DeSci in the Contect of Emerging Network Sovereigns

Lou de Kerhuelvez, Program Director at Foresight Institute, introduced the audience to new governance models called “Network Sovereignties.” New opportunities for coordination and governance are now possible with advancements in communication tools, collaboration, and technologies like blockchain, smart contracts, zero-knowledge proofs, and voting mechanisms.

Lou spoke about the flaws in the current ideas of network states - these models often lack proper governance structures, are centralized, oligarchic, territory-based, and primarily rely on exit strategies. Her proposed solution is network sovereignties, which serve as new institutional structures for global cooperation. Examples of this approach already exist in Vitalia and Edge City. Click here to read more about network sovereignty or how to participate in ongoing initiatives.

LabDAO - Accessible BioML Tools, Ownable Discoveries

How we can move from funding drug target studies to developing an actual candidate molecules within the DeSci framework? In traditional early-stage molecule discovery, it can cost millions of dollars just to identify a molecule which binds to a target. However, in DeSci, we are allocating only a fraction of that amount to current research initiatives. A major cost driver for these studies is laboratory expenses. So, how do we achieve the same quality of discovery with much less funding?

Lab.Bio offers a solution. By leveraging the latest advanced machine learning models, we can integrate laboratory simulation into the early discovery process. Users can run generative models and simulators to fast-track the discovery process, explore generated molecules, manage results, and retain ownership of their work. The Lab.Bio platform will be launching soon. For more information, visit LabDAO.

AminoChain - An Introduction to Decentralized Biobanking

AminoChain’s Founder and CEO, Casper Barnes, took the stage to announce the first decentralized biobank for enterprise healthcare institutions. Currently the process of donating bio-samples for scientific research is deeply flawed and fails to utilize the millions of unused samples across the US effectively. AminoChain aims to address the growing problem of misaligned incentives and mistrust in biomedical research with decentralized biobanking.

With decentralized biobanking, leveraging AminoChain’s software, biobanks can operate as nodes within a network that fosters collaboration by sharing samples and licensing agreements transparently and securely, while involving patients in the process. AminoChain’s goal is to create the Amazon for bio-samples, transforming biobanks worldwide into “shoppable specimen center experiences.”

Pitch Competition with Nucleate Activator’s Program

As part of the Molecule X Nucleate partnership, we decided to sponsor a pitch competition for participants in Nucleate’s German Activator program. Four young companies took to the stage to present their innovative ideas to the audience, who then had the power to vote for their favorite project. 

Fluvion

Fluvion’s advanced bioreactors are designed to efficiently scale and utilize secretory epithelial cells for various industrial applications. This technology enables the sustainable and economic production of biologic liquids such as milk, venoms, musk, silk, and complex pharmaceutical ingredients, all without the use of animals and without generating greenhouse gas emissions.

Jellyfish Bio

Jellyfish Bio is an AI platform for blood biomarker discovery. They leverage AI and continuous monitoring to create comprehensive, well-characterized individual patient profiles, addressing the heterogeneity of genetic diseases. By integrating genetics, wearable data, and blood biomarkers, they enable personalized treatment plans, drug repurposing analysis, and new outcome measures. 

Silica Corpora

Silica Corpora is an AI-driven company specializing in the de novo design, optimization, and screening of antibodies. They focus on epitope-specific screening and are developing tools like Ep-Mapper for epitope mapping.

EscapeAgent

EscapeAgent revolutionizes gene therapy with a potent endosomal escape enhancer, tackling delivery inefficiencies. They hope to enable efficient gene therapy by reducing complexity by using a drug master file!

The winner? Silica Corpora, with their De Novo design of antibody therapeutics. We want to thank Nucleate and all the participants for their incredible work, and we look forward to seeing each project develop and thrive.

That’s all for now folks!

Thank you to all our speakers, participants, and attendees for making DeSci.Berlin an unforgettable event. For those that weren’t able to make it, we’re in the process of uploading all of the talk onto our Youtube page, so they may live on in our hearts, minds, and Youtube playlists forever. See you next year!

Ella McCarthy-Page
Feb 13, 2024
min read

Even the smallest mutations in our genetic code can have damaging effects, cascading into an array of disease pathologies. In an effort to negate these effects,  VitaDAO, a key player in Decentralized Science, has partnered with Dr. Michael Torres and Artan BIO to engineer a first-in-class therapy that aims to suppress deleterious codon mutations. The VitaDAO community voted to provide $91,300 worth of funding to Dr. Torres via Molecule’s Intellectual Property Non-Fungible Token (IP-NFT) protocol. To increase the opportunity for community involvement and further funding, the IP-NFT will be tokenized into Intellectual Property Tokens (IPTs), granting governance privileges to IPT holders in the VitaDAO community and beyond. 

What happens when DNA gets up to nonsense?

The ribosome, colloquially known as our protein printer, is continually walking itself down strands of genetic code, reading each building block like braille, and then summoning the corresponding amino acids, with the help of transfer RNA (tRNA). These amino acids string together, ultimately forming proteins. If a single building block, known as a nucleotide, mutates, it can alter the protein being created. Our proteins participate in every possible shade of bodily function, so changes in protein synthesis tend to cause a whole host of problems. 

One such nucleotide change results in mutations known as nonsense mutations. They occur when a single nucleotide mutates and forms a stop codon, which is effectively a force-eject button. Stop codons are generally reserved for the end of the entire protein sequence when the protein is ready to be sent off into the body, but in the case of nonsense mutations, these stop codons accidentally crop up elsewhere. When this happens, protein formation is halted prematurely, resulting in half-formed, non-functional proteins which can go on to cause mayhem in the body. Finding and correcting nonsense mutations is not a novel concept. In fact, our bodies do it already! However, we’re far from perfect - issues arise when genuine stop codons are recognized as well, and overridden when they should not be. Currently, the existing treatments also fall prey to this issue. 

The Science

To address the gap, Dr. Torres has invented a potential solution; an engineered system to suppress the outcome of a particular nonsense mutation, enabling the continuation of protein formation. His solution is unique in so far that it appears to be more discerning than other treatments, correctly identifying the problematic stop codon while ignoring genuine stop codons, and most importantly, not interfering with normal gene translation. Preliminary data produced in collaboration with Johns Hopkins University has supported Dr. Torres’ hypothesis, leading to VitaDAO’s decision to fund further investigation. 

Additionally, Dr. Torres has identified a delivery system that is adept at sneaking into cells in the heart, liver, skeletal muscle, and central nervous system. By integrating the engineered codon suppressor into this vector, he suspects that it will be the perfect vehicle to carry the therapeutic to exactly where it needs to go. This vector comes with the bonus of already being clinically validated, which enables the team to optimize its path to first-in-human studies, as certain risks have already been addressed. 

The Scientist

Dr. Torres, who holds a PhD in Cancer Biology from UT-Southwestern in Dallas, has previously co-founded ReCode Therapeutics, a clinical-stage genetic medicines company that has secured over $300M in funding. He now works as the CEO of CrossBridge Bio, an oncology-focused company focused on developing next-generation dual payload antibody-drug conjugates. Dr. Torres was introduced to Decentralized Science (DeSci) by longtime DeSci supporter Mike Baran from Pfizer Ventures, and was quickly attracted to the ability to leverage community engagement to critically evaluate and fund ideas. His extensive experience in drug development, as well as his aptitude for both science and entrepreneurship, make him the perfect candidate for VitaDAO and Molecule’s novel funding model.

“In essence, this model is a powerful tool for transforming ideas into tangible data, supporting future drug development, and creating valuable societal assets.” Dr. Michael Torres

A single solution for many diseases

As a seasoned drug developer, Dr. Torres understands the importance of having foresight when in the lab. In studying nonsense mutations, Dr. Torres observed that a specific nonsense mutation is prevalent in many proteins involved in cellular processes associated with aging such as DNA repair, epigenetic regulators, and tumor suppressors. As this mutation is conserved across many diseases, several clinical opportunities are possible. Under optimal conditions, this research has the potential to turn into a ubiquitous therapy that could be used to treat several health issues associated with aging. VitaDAO is particularly interested in the potential of a therapeutic that could reactivate tumor-suppressing proteins in cancer patients, aiming to slow down or even eradicate tumor growth, given their focus on age-related diseases. Some of the other diseases implicated with nonsense mutations are Duchenne muscular dystrophy, cystic fibrosis, spinal muscular atrophy, metabolic diseases, and neurologic disorders. 

About VitaDAO

VitaDAO is a community-owned collective dedicated to funding and advancing longevity science that can improve people's lives. They have a strong presence in the Decentralized Science community and have utilized the IP-NFT model multiple times. In addition to this, together with Molecule and Dr. Viktor Korochuk, VitaDAO launched the first tokenized research project in the form of IPTs. The IPT tokens, known as VITA-FAST have enabled direct community governance - a world first. 

Dr. Anthony Schwartz, a VitaDAO Entrepreneur in Residence, will act as the project manager for this project. He has founded at least 15 startups, primarily focused on autoimmune diseases and cancer, which have led to large financings and an FDA-approved product. He is also a lecturer at Johns Hopkins. 

“The emerging VitaDAO model can potentially change how new drugs are funded. I'm excited and motivated to help bring that model to fruition through VitaDAO's funding of new companies and blockchain capital raises (IP-NFT/IPT) and seamlessly transition these companies into traditional VC/Pharma financing to bring new drugs to the market.” Dr. Anthony Schwartz

What is an Intellectual Property Non-Fungible Token?

Intellectual Property Non-Fungible Tokens (IP-NFTs) bring IP rights, such as the right to data and patents from drugs developed by funded research, onchain by attaching IP rights to smart contracts. By unifying data and intellectual property rights into programmable, transactable, blockchain tokens, IP-NFTs represent an evolutionary step in the development and management of scientific research IP. To date, IP-NFTs have been used to register IP of more than $1.95M in scientific research. The Torres IP-NFT adds to this growing list. You can find the IP-NFT here

The IP-NFT artwork created to visually represent the project

Intellectual Property Tokens invite the community to participate 

“This revolutionary concept of IP tokenization allows community involvement in the drug development process, creating a mutually beneficial situation. For us, it enables unlocking additional capital in a collaborative manner. For the community, it gives them an opportunity to directly support projects in a manner previously unavailable.” Dr. Michael Torres

True to the belief of equitable and accessible scientific research, VitaDAO will be tokenizing the Torres IP-NFT into IPTs, fungible tokens enabling the distribution of IP rights to their holders, in order to raise funds for the science and empower the community to govern the resulting IP.  

Funding from sales of the IPTs will enable Dr. Torres and his team to insert the engineered fragment into the chosen vector and perform in vitro testing to validate its effectiveness. IPTs will enable individuals to actively govern the project and its results, such as new drugs developed from the team’s research. 

Granting community members the power to co-develop research projects harnesses the potential of incentive-aligned expertise, furthering decentralized science. Many decisions need to occur as this project unfolds, such as which other possible delivery vehicles to test, which disease indication is best suited for clinical testing, and how to raise additional funds. With the power of IP tokenization, the wisdom of the crowd now has the chance to influence those decisions.  

Join VitaRNA Crowdsale

Logan Bishop-Currey
Feb 5, 2024
min read

Strengthening Decentralized Science 

Sharing a mission of supporting early stage life sciences research and development, Molecule and Nucleate are joining forces to cultivate the next generation of bioentrepreneurs. A partnership between Molecule, a central player in the growing Decentralized Science (DeSci) ecosystem, and Nucleate, a leading organization in the development of biotech leaders, is a novel opportunity to engage and educate the scientific community about innovative ways to fund their cutting-edge research. Molecule’s unique decentralized funding infrastructure enables this synergistic alliance, connecting a global network of drug hunters, academics and science enthusiasts across the world, united in the common goal of advancing high-quality biomedical research.  

Nucleate and Molecule share a common culture of innovation. Like Nucleate, Molecule’s vision for the future of life sciences is where intellectual property value is shared by researchers, entrepreneurs and patients alike. DeSci is the mechanism through which this vision can come to fruition. Its principles of incentive alignment, community engagement, and human-centricity are critical in moving the needle of change forward. 

Molecule has created a legal & smart contract platform called an intellectual property non-fungible token (IP-NFT). The IP-NFT facilitates the assignment of IP rights to blockchain-based tokens, enabling the legal rights, data access, and economics around research projects to be seamlessly funded and traded. Leveraging this technology, Molecule is building an ecosystem of scientific supporters eager to fund researchers, and the partnership with Nucleate is instrumental in connecting researchers with this community.

“We are thrilled to partner with Nucleate and to support the next generation of biotech leaders. Through this partnership, we hope to expand the reach of decentralized science to every campus in the world, and build on what is already the largest global community of bio innovators.” Tyler Golato, Molecule CEO

“We couldn’t be more excited to be partnering with Molecule to enable translation of research from the University to the real world through community engagement. Through this partnership, we are proud to empower the next generation by launching the Nucleate - Molecule Venture Fellowship which aims to train students in the field of venture building while simultaneously increasing the number of academic research projects that lead to commercialization.”  Sammi Sison, Nucleate’s Co-President

Venture Fellows

Ten candidates will be selected from a global pool of Nucleate fellows for the Venture Fellows program in 2024, and will undergo thorough education in two key areas: the essentials of IP funding via Molecule’s token-based model, and the principles of Decentralized Science (DeSci). Equipped with this knowledge, they will support selected research projects to successfully showcase their science and secure funding via Molecule’s platform. The fellowship will last for 6 months, in which time the Venture Fellows will participate in deal flow discussions with researchers and university technology transfer offices (TTOs), scientific reviews of projects, product development, and community engagement. By the end of the fellowship, the candidates will have been exposed to many of the challenges facing early stage researchers, and will be well positioned to tackle them in the next stage of their careers. 

Applications for 10 positions are now open, and those interested in applying can check out the job description here and submit their CV and cover letter here. Applications from European candidates will close at the end of March, and applications from candidates in the U.S. and Taiwan will close at the end of April. 

The $100K DeSci Award

In addition to the partnership, Molecule has created a $100,000 DeSci Award that will be granted to a research program sourced and tokenized by a Nucleate Fellow. The money will ensure that the deserving project will have sufficient resources to advance to its next value inflection point. Molecule will also assist the winning team in spinning out their asset with IP-NFT formation and tokenization to further increase the ability of the DeSci ecosystem to participate in its development. 

About Molecule

Molecule enables funding at the earliest stages of translational research. Molecule’s products make IP effortlessly transactable through tokenization, enabling an incentive-aligned, community-driven approach to address inefficiencies in the translational research pipeline. Simply put, Molecule is building a future where smart people with good ideas can quickly fund and successfully de-risk them with community support. Since 2022, Molecule has raised $20+ million to further this goal.

 

About Nucleate

Nucleate is a non-profit organization dedicated to empowering the next generation of biotech leaders. With chapters spanning 23 geographic regions and participation from over 120 academic institutions, Nucleate sparks new intellectual communities and embeds emerging talent within a global biotech community. Through open-access educational programming, Nucleate helps democratize biotech innovation — removing barriers and helping founders concentrate on building transformational technologies.

FAQs

Comprehensive answers to your most commonly asked questions

How can I become a funder?

There are two avenues available for individuals interested in funding projects within the Molecule ecosystem: You can purchase DAO tokens during a token launch which will contribute towards their treasury. Alternatively, you can participate in IP token crowdsales, which allow you to directly fund certain research projects.

Token holders are conferred governance rights, allowing them to participate in decision-making.
These auctions are often conducted on Ethereum, using smart contracts to facilitate the execution of the fundraising without a trusted intermediary, and to ensure transparency and immutability.

What are IP-NFTs?

Intellectual Property Non-Fungible Tokens (IP-NFTs) are onchain intellectual property contracts. By unifying data and property rights into programmable, transactable, blockchain tokens in the internet of money, IP-NFTs represent an evolutionary step in the development and management of scientific research IP. 

To date, IP-NFTs have been used to register IP of more than $2M in scientific research including at many world-renowned universities.  

What are IP Tokens?

IP tokens (IPTs) are onchain memberships in IP-NFTs. When IP-NFT holders mint IPTs, they create tokenized IP commons managed by their members, accelerating progress of science through incentives to coordinate. IPTs enable IP governance, not ownership and milestone-based fundraising for scientific research. By minting IPTs, IP-NFT holders can incentivize contributors to IP development and enable their IP to be priced by free markets.

Do I need a crypto wallet to be a funder?

Yes, you do need a crypto wallet, as the transactions happen on the blockchain. If you do not have a wallet, we suggest starting with Metamask. Here is a thread on funding your wallet.

What if there are no active token sales?

If there are no active token sales, you may be able to purchase DAO tokens or IP tokens on the open market. These funds will not directly fund research, but will still confer governance rights, allowing you to actively participate in the Decentralised Science ecosystem.

Still have a question?

Drop us a message below, and our team at Molecule will be thrilled to hear from you.

"Molecule is a leader of the “new fashion” on how to distribute private grants to the most competitive and deserving scientists: it delivers grant in a fast, fair, and low working load manner."

Name Surname

Lead Researcher

“Molecule has not just paved the way for innovative funding of scientific research, but has also welcomed everyone to participate in molding the next era of medicine.”

Name Surname

Lead Researcher

Coming Soon
Aliquid Excepturi Vitae
Perferendis dolores voluptates eaque et consequatur. Id quae exercitationem est sint reprehenderi Perspiciatis dolore quo alias eaque in repellat saepe quis deserunt. Consequatur consequatur qui veniam quam accusamus eaque asperiores qui
$00.000.000
raised of
$ 31,500.00
goal
Funded by
VitaDAO
and
1
MORE
Coming Soon
AthenaDAO Token Launch
AthenaDAO is raising funds tu support to advance women’s health research.
$ -
raised of
$ 350,000
goal
Funded by
AthenaDAO
and
1
MORE
Coming Soon
Consequatur Minima
Atque nesciunt veniam. Voluptas consectetur id quas amet eos at sed tempora labor Vol maiores odit quas facere repellat ea qui officia. Sit molestiae sunt perferendis eum. Et dignissimos aut earum repellat rerum omnis et doloribus autem. N
$00.000.000
raised of
$00.000.000
goal
Funded by
CryoDAO
and
3
MORE
Now Selling
Unde Quia Libero
Ratione consequatur ut. Qui rerum incidunt inventore ipsum in perferen Qui similique quibusdam non est deleniti explicabo dolores sint. Vero in rem dolor animi explicabo qui error qui. Voluptate et numquam magnam. Ipsa dolore sint. Volupta
$00.000.000
raised of
$00.000.000
goal
Funded by
CryoDAO
and
3
MORE
Successfully funded
Maiores Quia Suscipit
Earum et alias quasi eum autem occaecati ex nostrum. Assumenda ea et sed rerum maiores voluptatibus. Possimus quisquam assumenda dolorem excepturi eligendi. Repudiandae nostrum quasi ratione hic id molestiae autem at placeat.
$00.000.000
raised of
$00.000.000
goal
Funded by
HairDAO
and
2
MORE